【摘要】 目的观察抗CD20单抗(利妥昔单抗)联合环磷酰胺、长春新碱、阿霉素及泼尼松(CHOP方案)治疗初诊B细胞性非霍奇金淋巴瘤的临床疗效。方法36例初治患者采用标准的CHOP方案治疗,每3周1个疗程,共6个疗程。利妥昔单抗静滴剂量为375 mg/m2,每3周输注1次,连续4次或6次。观察疗效及副作用。结果在36例患者中,66.7%获得完全缓解(CR),总有效率(OR)为100%。36例患者共随访了12～43个月,患者24个月的疾病无进展生存(PFS)率为80.5%。主要不良反应为与输注相关的不良反应如发热、恶心、呕吐和中性粒细胞减少、贫血和血小板减少。结论利妥昔单抗联合CHOP方案治疗初治弥漫性大B细胞淋巴瘤和滤泡性淋巴瘤具有良好的临床疗效和安全性。更多还原

【Abstract】 Objective To evaluate the efficacy of rituximab combined with cyclophosphamide,vin-cristine,doxorubicin and prednisone(CHOP regimen) in treating the initially diagnosed non-Hodgkin’s lymphoma(NHL).Methods Thirty-six patients’ chemotherapy was conducted with standard CHOP regimen every 3 weeks,for 6 courses.Rituximab was given at the dose of 375 mg/m2,every 1 or 3 weeks,for 4 or 6 courses.The efficacy and the toxicity were observed.Results: In 36 patients who were evaluated for efficacy,complete response rate and overall response rate were achieved at 66.7% and 100% respectively.Thirty-six patients were followed-up from 12 to 43 months(median 25 months) and estimated progress free survival(PFS) rate of 24 months was 80.5 %.The major toxicities were infusion related response fever,nausea,vomiting and neutropenia,anemia and thrombocytopenia.Conclusion Rituximab combined with CHOP regimen can be successfully applied to the therapy of initially diag-nosed B cell NHL including diffuse large B cell lymphoma and follicular lymphoma with mild toxicity.更多还原